vaccin
one
power
public
health
intervent
centuri
prevent
estim
six
million
death
year
public
point
view
vaccin
program
result
cost
save
exceed
invest
last
year
academ
scientist
vaccin
industri
develop
larg
number
vaccin
includ
approxim
vaccin
licens
human
use
veterinari
vaccin
current
use
vaccin
classifi
sever
type
classif
also
reflect
histor
step
vaccin
develop
type
includ
vaccin
differ
infecti
agent
bacteria
virus
parasit
vaccin
obtain
differ
method
develop
vaccin
contain
singl
multipl
antigen
recombin
vaccin
figur
supplementari
tabl
first
vaccin
smallpox
vaccin
introduc
jenner
year
ago
use
heterolog
viru
contain
materi
origin
infect
cow
cowpox
protect
human
smallpox
develop
intern
use
vaccin
led
complet
erad
smallpox
one
greatest
achiev
medicin
target
vaccin
develop
began
lui
pasteur
discoveri
pathogen
microorgan
less
virul
cultiv
suboptim
condit
treat
differ
chemic
introduc
concept
attenu
vaccin
later
exploit
gener
mani
vaccin
includ
vaccin
anthrax
rabi
later
progress
cell
cultur
technolog
enabl
cultur
mammalian
cell
allow
propag
virus
result
effect
attenu
vaccin
polio
measl
mump
rubella
influenza
infecti
diseas
third
group
vaccin
gener
chemic
inactiv
infecti
bacteria
virus
well
bacteri
toxin
toxoid
vaccin
applic
increas
temperatur
inactiv
chemic
product
differ
vaccin
still
use
industri
vaccin
cholera
polio
rabi
japanes
enceph
infecti
diseas
develop
molecular
genet
bacteriolog
biochemistri
contribut
significantli
understand
molecular
structur
live
cell
allow
identif
pathogen
compon
potenti
suitabl
vaccin
gener
exploit
idea
result
long
list
socal
subunit
vaccin
includ
vaccin
haemophilu
influenza
meningococcu
pneumococcu
polysaccharid
conjug
carrier
protein
hepat
b
plasmaderiv
protein
antigen
advent
molecular
biolog
result
next
breakthrough
medicin
industri
achiev
gene
engin
dramat
influenc
construct
vaccin
sinc
recombin
technolog
introduc
develop
differ
vaccin
type
live
attenu
recombin
bacteria
virus
well
product
toxin
protein
antigen
use
recombin
host
hepat
b
hbv
vaccin
first
subunit
vaccin
gener
gene
engin
techniqu
year
ago
express
clone
copi
hbv
surfac
antigen
hbsag
yeast
cell
result
product
noninfecti
viruslik
particl
vlp
allow
replac
previous
gener
plasmaderiv
vaccin
success
hbv
vaccin
strongli
stimul
develop
recombin
vaccin
base
viral
structur
protein
mark
begin
new
era
ration
design
vlp
platform
gener
prophylact
therapeut
vaccin
use
principl
viral
coat
protein
cp
express
heterolog
host
vaccin
cervic
cancer
gardasil
cervarix
hepat
hecolin
malaria
rt
construct
clinic
test
licens
human
use
subsequ
decad
import
stress
rt
vaccin
first
among
licens
vaccin
contain
vlp
carrier
hbsag
incorpor
foreign
antigen
cs
artifici
viruslik
structur
deriv
plant
viru
protein
well
known
due
viru
assembl
studi
perform
sinc
base
use
carrier
protein
chemic
coupl
peptid
antigen
promis
vaccin
candid
hayn
et
al
gener
experiment
vaccin
use
gene
engin
approach
instead
chemic
coupl
combin
tobacco
mosaic
viru
tmv
cp
gene
extens
encod
ctermin
locat
aalong
antigen
peptid
polioviru
result
vlp
purifi
recombin
bacteri
cell
immunogen
stimul
format
antibodi
polioviru
rat
result
togeth
hbsag
introduc
use
vlp
central
carrier
element
mani
experiment
licens
vaccin
addit
studi
clearli
demonstr
nonpathogen
virus
also
suitabl
vaccin
gener
introduct
relev
antigen
structur
virus
deriv
possess
sever
characterist
highli
import
use
vaccin
like
import
properti
virus
vlp
structur
organ
structur
virus
construct
hundr
thousand
highli
order
cp
molecul
serv
repeat
antigen
mammalian
immun
system
antigen
viru
surfac
stimul
b
cell
crosslink
b
cell
receptor
induc
longlast
antibodi
respons
addit
virus
optim
size
shape
rigid
enter
lymphat
system
pore
lymph
vessel
facilit
traffick
viral
particl
vlp
lymph
node
uptak
antigenpres
cell
apc
moreov
virus
vlp
encapsul
specif
hostderiv
nucleic
acid
dna
rna
stimul
tolllik
receptor
apc
serv
natur
vaccin
adjuv
plant
virus
vlp
figur
compar
vlp
addit
advantag
vaccin
carrier
structur
well
known
plant
virus
abl
infect
mammalian
organ
therefor
probabl
preexist
immun
plant
virus
consider
lower
compar
vlp
deriv
mammalian
virus
eg
hbv
papilloma
viru
plant
virus
assembl
singl
cp
molecul
demonstr
remark
structur
flexibl
allow
differ
manipul
disassemblyreassembl
well
chemic
genet
modif
enabl
ration
design
vaccin
introduct
differ
antigen
deriv
infecti
agent
allergen
selfmolecul
addit
plant
vlp
artifici
gener
vlp
contain
replic
nucleic
acid
prevent
revers
vaccin
infecti
virus
seriou
risk
factor
attenu
viral
vaccin
technolog
viewpoint
plant
virus
vlp
produc
differ
recombin
host
bacteria
yeast
plant
eukaryot
cell
cgmp
condit
mention
structur
flexibl
plant
virus
allow
construct
univers
vaccin
platform
review
summar
publicli
avail
data
vaccin
deriv
plant
virus
emphas
newest
develop
construct
experiment
vaccin
use
two
databas
sourc
inform
pubm
databas
us
nation
institut
health
http
wwwncbinlmnihgovpubm
web
scienc
http
appswebofknowledgecom
literatur
search
demonstr
rapidli
grow
interest
plant
virus
vaccin
carrier
exampl
cumul
search
term
plant
viru
vaccin
web
scienc
yield
public
record
least
public
end
reveal
search
plant
viru
deriv
serv
compon
least
experiment
vaccin
infecti
diseas
anticanc
vaccin
vaccin
allergi
autoimmun
diseas
exampl
literatur
citat
summar
supplement
tabl
increas
interest
recent
public
stimul
us
summar
discuss
latest
develop
design
vaccin
base
plant
virus
descript
plant
vlp
applic
found
sever
recent
review
articl
effort
vaccin
industri
result
compar
long
list
licens
prophylact
vaccin
effect
prevent
infect
differ
infecti
agent
supplementari
tabl
howev
efficaci
current
vaccin
moder
even
poor
case
ensur
longlast
protect
erad
correspond
diseas
addit
urgent
need
vaccin
viral
bacteri
pathogen
human
immunodefici
viru
tuberculosi
malaria
mani
agent
well
emerg
diseas
zika
viru
dengu
ebola
sar
therefor
interest
altern
solut
gener
new
vaccin
improv
exist
vaccin
continu
grow
experiment
vaccin
base
plant
virus
construct
test
year
sinc
first
tmvbase
vaccin
develop
polioviru
chapter
discuss
recent
develop
plant
virusderiv
prophylact
vaccin
import
pathogen
influenza
malaria
case
plant
virusderiv
vaccin
peptid
vaccin
genet
fuse
chemic
coupl
viral
cp
peptid
vaccin
stimul
format
neutral
antibodi
ensur
protect
correspond
pathogen
anim
model
suppl
tabl
advantag
approach
includ
reduc
influenc
short
peptid
structur
integr
viral
carrier
easi
product
experiment
vaccin
howev
antigen
frequent
linear
aa
sequenc
spatial
complex
structur
involv
differ
part
antigen
protein
antigen
peptidebas
vaccin
suitabl
stimul
protect
via
immun
respons
therefor
sever
author
suggest
usag
whole
protein
antigen
result
epitop
structur
close
relat
nativ
one
elicit
neutral
antibodi
immun
genet
fusion
whole
antigen
protein
viral
cp
neg
influenc
vlp
format
case
howev
sometim
plant
viral
coat
abl
accommod
even
long
antigen
sequenc
surfac
altern
genet
fusion
approach
result
antigen
present
chemic
coupl
physic
bind
antigen
vlp
surfac
use
bind
partner
molecul
success
exampl
gener
vaccin
use
chemic
enzymat
coupl
whole
antigen
includ
studi
experiment
vaccin
francisella
tularensi
influenza
yersinia
pesti
plasmodium
vivax
zika
viru
method
use
incorpor
whole
antigen
sequenc
viral
cp
allow
preserv
viral
morpholog
discuss
recent
review
articl
sever
plant
virusbas
vaccin
test
toler
safeti
efficaci
human
clinic
trial
first
vaccin
edibl
vaccin
rabi
contain
recombin
antigen
deriv
rabi
viru
protein
fusion
peptid
deriv
g
n
protein
incorpor
nterminu
alfalfa
mosaic
viru
almv
introduct
chimer
gene
tmvbase
plant
vector
transient
express
spinach
leav
result
almvlik
particl
expos
rabi
epitop
inclus
raw
spinach
leav
contain
vlp
diet
human
volunt
led
signific
antibodi
respons
rabi
viru
plant
viru
carrier
pioneer
studi
clearli
demonstr
potenti
plant
virusbas
carrier
gener
human
vaccin
later
sever
vaccin
candid
construct
base
almv
carrier
figur
malaria
one
biggest
health
threat
caus
hundr
million
case
death
countri
especi
africa
exist
vaccin
rt
demonstr
limit
efficaci
clinic
trial
recent
public
summar
result
phase
studi
assess
malaria
transmissionblock
vaccin
base
recombin
fusion
p
falciparum
antigen
plant
viru
almv
vaccin
candid
produc
whole
plant
cgmp
condit
demonstr
accept
safeti
toler
induc
antibodi
depend
inject
vaccin
dose
howev
gener
antibodi
produc
expect
reduct
p
falciparum
transmiss
mosquito
human
host
cell
author
conclud
necessari
improv
formul
vaccin
increas
proport
antigen
incorpor
plant
vlp
recent
plant
virusderiv
vlp
suggest
activ
compon
vaccin
malaria
author
recommend
usag
thrombospondinrel
adhes
protein
trap
antigen
necessari
plasmodium
vivax
sporozoit
motil
liver
cell
invas
vaccin
design
base
cucumb
mosaic
viru
cmv
vlp
chemic
coupl
trap
antigen
formul
microcrystallin
tyrosin
mct
adjuv
vaccin
formul
contain
vlp
increas
antibodi
product
trap
compar
produc
antigen
alon
vlpbase
vaccin
formul
mct
confer
signific
protect
challeng
test
recombin
p
berghei
suggest
mct
use
advantag
adjuv
altern
prophylact
vlp
vaccin
next
import
viral
infect
influenza
caus
death
global
everi
year
today
licens
inactiv
vaccin
produc
routin
howev
exist
vaccin
ensur
complet
protect
circul
influenza
strain
reason
low
vaccin
efficaci
low
level
hemagglutinationinhibit
antibodi
influenza
strain
variat
hemagglutinin
ha
sequenc
improv
flu
vaccin
use
stronger
adjuv
increas
amount
ha
well
addit
new
antigen
neuraminidas
matrix
protein
influenza
vaccin
increas
efficaci
differ
peptid
antigen
includ
peptid
deriv
nucleoprotein
protein
test
use
plant
virus
vaccin
carrier
adjuv
demonstr
signific
protect
challeng
differ
anim
model
see
exampl
supplementari
tabl
one
experiment
vaccin
current
test
human
trial
aim
evalu
safeti
reactogen
papaya
mosaic
viru
papmv
vlp
adjuv
use
season
flu
trival
vaccin
healthi
volunt
efficaci
plant
vlpadjuv
flu
vaccin
yet
report
earlier
public
suggest
filament
papmv
vlp
contain
consensu
peptid
influenza
matrix
protein
increas
surviv
immun
mice
use
adjuv
togeth
trival
inactiv
flu
vaccin
result
demonstr
strong
adjuv
properti
filament
plant
vlp
influenza
vaccin
plant
virusbas
peptid
vaccin
also
evalu
veterinari
trial
vaccin
base
cowpea
mosaic
viru
cpmv
protect
vaccin
dog
lethal
challeng
canin
parvoviru
anoth
vaccin
foot
mouth
diseas
viru
fmdv
design
use
bamboo
mosaic
viru
bamv
vector
aa
fmdv
protein
immun
swine
protect
fmdv
challeng
anoth
veterinari
trial
demonstr
vaccin
safeti
protect
pig
porcin
circoviru
pcv
vaccin
inactiv
cmvbase
vaccin
contain
incorpor
pcv
cp
epitop
cancer
one
lead
caus
death
global
respons
estim
million
death
current
alongsid
surgeri
chemotherapi
radiat
cancer
immunotherapi
becom
import
compon
cancer
treatment
cancer
immunotherapi
histori
began
first
observ
signific
regress
sarcoma
patient
accident
infect
streptococcu
bacterium
william
coley
american
surgeon
use
heatinactiv
bacteria
treat
larg
number
patient
suffer
inoper
cancer
therapi
method
result
cure
patient
howev
method
later
replac
radiat
chemotherapi
due
danger
infect
risk
absenc
reproduc
result
next
import
mileston
develop
cancer
immunotherapi
find
old
et
al
demonstr
antitumor
activ
tuberculosi
vaccin
bcg
mous
model
vaccin
introduc
treatment
bladder
cancer
use
clinic
sinc
key
event
cancer
immunolog
discuss
sever
recent
review
articl
sever
cell
proteinbas
anticanc
vaccin
approv
use
clinic
test
latestag
clinic
trial
autolog
dendrit
cell
vaccin
recombin
virusbas
vaccin
peptidebas
vaccin
dna
vaccin
human
tumor
wholecel
vaccin
howev
part
clinic
test
anticanc
vaccin
demonstr
limit
efficaci
comparison
tradit
treatment
requir
develop
new
strategi
combin
differ
approach
one
new
approach
vaccin
cancer
base
usag
nanoparticl
liposom
carbon
nanotub
synthet
biodegrad
biocompat
polym
inorgan
nanoparticl
vlp
differ
combin
particl
vlp
repres
power
flexibl
tool
gener
activ
compon
cancer
vaccin
demonstr
numer
preclin
studi
review
see
alreadi
discuss
advantag
vlp
vaccin
multipl
antigen
size
vlp
allow
enter
lymphat
system
capabl
encapsul
nucleic
acid
stimul
tolllik
receptor
result
vlp
abl
induc
strong
cell
respons
import
requir
therapeut
vaccin
cancer
moreov
vlp
technolog
alreadi
use
prevent
cancer
papilloma
virusderiv
vlp
effici
protect
immun
individu
cervic
cancer
plant
virus
includ
nativ
recombin
virus
well
noninfecti
deriv
vlp
consid
nanoparticl
structur
antitumor
activ
sinc
mccormick
et
al
introduc
melanomaspecif
peptid
tmv
use
recombin
fusion
chemic
coupl
test
vaccin
tumor
challeng
model
author
observ
direct
tmv
uptak
dendrit
cell
enhanc
product
interferon
ifng
interestingli
vaccin
prepar
chemic
coupl
peptid
tmv
ensur
better
surviv
anim
recombin
vaccin
vaccin
variant
formul
cpg
dna
adjuv
import
vaccin
formul
also
demonstr
recent
studi
use
icosahedr
cmv
vlp
chemic
coupl
peptid
deriv
lymphocyt
choriomening
viru
lcmv
vaccin
formul
mct
cpg
alum
adjuv
test
aggress
mous
melanoma
model
vlp
adjuv
mct
effect
retard
develop
tumor
effect
compar
cpg
dna
use
adjuv
wherea
alum
ineffect
slow
tumor
growth
recent
studi
suggest
highli
interest
immunotherapi
approach
three
differ
icosahedr
plant
virusderiv
nanoparticl
chemic
coupl
breast
cancer
epitop
effici
elicit
format
antibodi
receptor
overexpress
breast
cancer
cell
addit
three
vaccin
stimul
tcellmedi
immun
respons
test
separ
sequenti
use
vaccin
reduc
immun
respons
vlp
carrier
improv
format
antibodi
peptid
suggest
primeboost
strategi
consider
reduc
tumor
develop
enhanc
surviv
rate
mous
tumor
model
studi
clearli
demonstr
immun
respons
includ
format
antibodi
secret
ifng
activ
tcell
import
factor
immunotherapi
interestingli
plant
vlp
deriv
cpmv
demonstr
better
immunotherapeut
properti
deriv
cowpea
chlorot
mottl
viru
ccmv
sesbania
mosaic
viru
semv
therefor
addit
studi
need
understand
differ
differ
plant
vlp
use
carrier
anticanc
vaccin
exampl
plant
virusbas
cancer
vaccin
correspond
literatur
citat
summar
supplementari
tabl
analysi
sever
recent
public
reveal
potenti
applic
unmodifi
plant
vlp
without
introduc
antigen
cancer
immunotherapi
agent
one
studi
author
compar
differ
prepar
nanoparticl
deriv
cpmv
immunotherapeut
agent
murin
ovarian
cancer
model
nativ
cpmv
particl
contain
viral
rna
induc
pronounc
therapeut
effect
surviv
experiment
anim
comparison
empti
cpmv
vlp
produc
plant
insect
cell
enhanc
immunomodulatori
effect
appar
due
presenc
encapsid
ssrna
nativ
cpmv
virion
activ
tolllik
receptor
interestingli
chosen
recombin
host
also
influenc
immunestimul
properti
produc
plant
vlp
anoth
studi
structur
variant
plant
virusderiv
nanoparticl
sever
speci
use
situ
vaccin
icosahedr
cpmv
three
variant
tmv
nativ
vitro
rnatempl
assembl
short
tmv
spheric
tmv
produc
thermal
treatment
nativ
virion
result
suggest
superior
immunestimul
properti
cpmv
compar
structur
variant
tmv
confirm
antigen
multipl
one
import
factor
involv
elicit
strong
immun
respons
one
possibl
explan
enhanc
immunestimul
properti
cpmv
mous
melanoma
model
abil
vlp
recruit
monocyt
tumor
microenviron
lead
infiltr
neutrophil
natur
killer
cell
result
tumor
growth
inhibit
author
suggest
intrins
properti
plant
virus
allow
develop
cancer
vaccin
clinic
use
howev
detail
mechan
immun
stimul
remain
elucid
vaccin
also
highli
promis
treatment
allergi
autoimmun
neurodegen
diseas
demonstr
latest
studi
similar
antimicrobi
anticanc
vaccin
plant
virus
vlp
serv
carrier
structur
correspond
antigen
import
diseas
develop
one
challeng
diseas
term
therapi
develop
alzheim
diseas
ad
million
peopl
worldwid
suffer
dementia
caus
format
plaqu
contain
proteolyt
fragment
amyloid
precursor
protein
aa
exist
therapi
experiment
approach
includ
use
monoclon
antibodi
vaccin
small
impact
diseas
progress
accord
recent
opinion
vaccin
prophylact
level
specif
antibodi
suffici
high
target
oligomer
speci
peptid
size
epitop
includ
vaccin
less
aa
prevent
stimul
pathogen
tcell
respons
concept
ad
vaccin
exist
year
howev
first
clinic
trial
use
vaccin
contain
aggreg
peptid
aa
result
case
tcellmedi
brain
inflamm
later
experiment
vaccin
consist
peptid
bacteriophag
conjug
produc
strong
antibodi
respons
without
signific
tcell
respons
mice
plant
virus
deriv
vlp
also
consid
epitop
carrier
alzheim
vaccin
potenti
vaccin
candid
gener
use
infecti
cmv
fuse
peptid
purifi
plant
biomass
recent
construct
plant
vlp
platform
figur
base
cmv
genet
incorpor
univers
tcell
epitop
interior
particl
chemic
coupl
peptid
vlp
surfac
sera
obtain
immun
mice
shown
recogn
alzheim
plaqu
human
brain
section
suggest
vaccin
induc
product
specif
antibodi
allerg
disord
among
common
chronic
diseas
europ
recent
decad
patient
suffer
allergi
avoid
allergen
use
antihistamin
medic
altern
allergenspecif
immunotherapi
ait
avail
treatment
reduct
allergi
symptom
therapi
crude
allergen
extract
contain
mixtur
nativ
allergen
protein
use
typic
disadvantag
ait
risk
anaphylact
reaction
long
durat
therapi
low
qualiti
natur
extract
use
ait
unsatisfactori
efficaci
treatment
peanut
allergi
frequent
caus
anaphylact
reaction
death
among
food
allergi
current
safe
effect
therapi
peanut
allergi
especi
patient
sever
allergi
recent
construct
sever
plant
virusbas
immunolog
optim
vaccin
peanut
allergi
chemic
coupl
peanut
allergen
ara
h
ara
h
well
mixtur
protein
purifi
roast
peanut
extract
cmv
vlp
result
vaccin
caus
allerg
reaction
induc
specif
igg
antibodi
protect
peanutsensit
mice
anaphylact
shock
notabl
immun
singl
allergencontain
vlp
ensur
protect
challeng
complex
allergen
mixtur
suggest
new
vaccin
strategi
treatment
peanut
allergi
exampl
vlp
usag
treatment
allerg
diseas
summar
recent
publish
review
articl
allergi
cat
affect
human
popul
preval
increas
similar
food
allergi
current
cat
allergi
treatment
includ
avoid
exposur
use
antihistamin
steroid
longterm
subcutan
immunotherapi
measur
partial
effect
elimin
allerg
reaction
addit
immunotherapi
bound
result
safeti
issu
predomin
cat
allergen
secretoglobulin
fel
secret
cat
sebac
salivari
gland
gener
cmvbase
vaccin
contain
recombin
fel
allergen
use
chemic
coupl
demonstr
vlp
coupl
effect
reduc
allerg
reaction
stimul
format
fel
igg
protect
sensit
mice
anaphylact
shock
moreov
bachmann
collabor
propos
new
strategi
treatment
fel
allergi
involv
immun
cat
fel
allergen
induc
antibodi
exhibit
strong
neutral
abil
might
result
reduc
symptom
allerg
cat
owner
monoclon
antibodi
mab
produc
immort
hybridoma
cell
repres
new
way
treat
differ
diseas
sinc
approv
first
mab
prevent
kidney
transplant
reject
numer
mab
use
clinic
treatment
cancer
bacteri
viral
infect
variou
cardiovascular
respiratori
neurolog
autoimmun
diseas
mab
proven
effici
agent
treat
chronic
inflammatori
diseas
via
select
inhibit
cytokin
excess
produc
sever
diseas
condit
take
account
high
cost
side
effect
mab
therapi
signific
interest
replac
mab
treatment
activ
immun
autolog
protein
includ
interleukin
base
idea
gener
plant
vlpbase
vaccin
test
mice
psoriasi
model
vaccin
mice
demonstr
similar
reduct
psoriat
symptom
compar
anim
passiv
immun
antibodi
moreov
vaccin
elicit
protect
effect
suboptim
condit
involv
older
mice
low
vaccin
dose
knowledg
obtain
success
studi
human
vaccin
mab
treatment
transfer
develop
veterinari
vaccin
well
known
exampl
allerg
hypersensit
link
activ
eosinophil
enhanc
product
interleukin
cell
eosinophil
count
effect
reduc
specif
human
mab
use
treatment
human
asthma
activ
vaccin
plant
conjug
instead
mab
induc
potent
antibodi
respons
hors
reduc
symptom
insect
bite
hypersensit
simultan
vaccin
significantli
influenc
blood
eosinophil
count
parasit
load
vaccin
hors
anoth
exampl
cmvbase
therapeut
vaccin
vaccin
reduc
product
dog
hors
suffer
itch
atop
dermat
insect
bite
hypersensit
anim
vaccin
well
toler
improv
diseas
symptom
last
year
nerv
growth
factor
ngf
key
molecul
involv
regul
neuron
regener
injuri
pain
percept
suggest
promis
target
osteoarthr
oa
treatment
human
monoclon
antibodi
ngf
significantli
suppress
pain
associ
latestag
oa
base
construct
cmvbase
ngf
vaccin
demonstr
therapeut
efficaci
show
allevi
spontan
pain
behavior
surgic
induc
murin
oa
vaccin
product
one
challeng
industri
process
sever
import
factor
influenc
vaccin
develop
market
one
time
requir
bring
new
vaccin
develop
phase
market
exceed
year
includ
year
averag
design
construct
valid
commenc
industri
manufactur
next
factor
signific
human
financi
resourc
necessari
develop
sustain
ondemand
product
vaccin
vaccin
industri
continu
solv
problem
long
life
cycl
vaccin
high
facil
cost
complex
global
vaccin
demand
long
vaccin
develop
period
addit
challeng
neg
influenc
avail
vaccin
emerg
infecti
diseas
ebola
viru
sarscov
zika
viru
chickungunja
viru
other
moreov
chosen
antigen
structur
use
vaccin
manufactur
differ
correspond
nativ
antigen
reduc
even
prevent
neutral
abil
gener
antibodi
aspect
critic
influenc
develop
process
vaccin
pathogen
especi
infecti
agent
high
genet
variat
hiv
exampl
pathogen
effect
vaccin
despit
mani
year
effort
academ
scientist
vaccin
industri
one
challeng
aspect
mention
factor
possibl
import
vaccin
develop
futur
fact
latest
studi
suggest
microbiom
digest
track
recipi
influenc
efficaci
vaccin
effect
observ
human
laboratori
mice
suggest
need
investig
shown
review
plant
virus
noninfecti
deriv
vlp
intens
studi
immunolog
activ
multival
structur
use
gener
new
prophylact
therapeut
vaccin
human
anim
infecti
agent
cancer
autoimmun
diseas
compar
vlp
plant
vlpbase
vaccin
addit
advantag
flexibl
vaccin
construct
eas
vlp
product
purif
stabil
low
risk
preexist
immun
properti
make
plant
virus
attract
altern
anim
human
vlp
today
plant
virusbas
vaccin
commerci
avail
howev
sever
vaccin
platform
develop
allow
construct
new
vaccin
compar
short
period
time
experiment
vaccin
platform
toler
incorpor
larg
antigen
even
fullsiz
protein
viral
structur
without
influenc
particl
morpholog
immunestimul
properti
nativ
spatial
structur
recombin
antigen
highli
import
elicit
antibodi
neutral
activ
longlast
immun
futur
recombin
vlp
vaccin
must
contain
multipl
copi
correctli
fold
antigen
well
differ
immunostimul
compon
includ
tcell
epitop
nucleic
acid
achiev
discuss
suggest
vaccin
base
plant
virusbas
carrier
use
address
differ
challeng
vaccin
construct
develop
new
approv
prophylact
therapeut
vaccin
human
veterinari
use
come
year
